BioNTech SE (BNTX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Mainz, Germany. El CEO actual es Ugur Sahin.
BNTX tiene fecha de IPO 2019-10-10, 6,772 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $25B.
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, that develops and commercializes immunotherapies targeting cancer and infectious diseases. The company's pipeline includes multiple therapeutic programs: personalized cancer vaccines (FixVac candidates), neoantigen-specific immunotherapies including Autogene cevumeran, mRNA intratumoral immunotherapies, chimeric antigen receptor T cell therapies, checkpoint immunomodulators, and monoclonal antibodies, with most candidates in clinical development stages. BioNTech also develops prophylactic vaccines for COVID-19 and influenza, along with therapies for rare diseases. The company maintains strategic collaborations with major pharmaceutical and biotechnology partners including Pfizer, Sanofi, Genentech, Regeneron, and others to advance its diverse clinical pipeline.
